HARNESS-1 (RC220 + Osimertinib)
EGFR-mutant Non-Small Cell Lung Cancer (EGFRm NSCLC)
Phase 1a/bActive
Key Facts
Indication
EGFR-mutant Non-Small Cell Lung Cancer (EGFRm NSCLC)
Phase
Phase 1a/b
Status
Active
Company
About Race Oncology
Racura Oncology is advancing RC220, a reformulated version of the anthracene-based drug (E,E)-bisantrene, through three clinical programs in AML, EGFRm NSCLC, and solid tumors. The company's key innovations include the 2025 discovery of its novel MYC-silencing mechanism, enabling new composition-of-matter patents, and the demonstration of cardioprotection when combined with anthracyclines. Operating with a lean, virtual model, Racura's strategy is to progress its clinical portfolio while actively seeking strategic partnerships or M&A to accelerate global commercialization.
View full company profile